China-based MicroPort Scientific Corp’s spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has announced positive follow-up results for its in-house developed transcatheter mitral valve replacement system. The system has successfully treated multiple severe cases of mitral regurgitation, a condition characterized by the leakage of the mitral valve.
One-Year Follow-Up and Patient Outcomes
The first patient to undergo the procedure has recently completed a one-year follow-up, marking a significant milestone. The remaining patients have shown a significant reduction in mitral regurgitation, with no recurrence, no perivalvular leakage, and no left ventricular outflow tract obstruction. Additionally, there has been a notable improvement in heart function-related indicators. Patients have reported a significant improvement in the discomfort caused by mitral regurgitation.
Innovative Features of MicroPort CardioFlow’s Transcatheter Mitral Valve Replacement Product
Billed as the world’s first dry valve transcatheter mitral valve replacement product in clinical use, MicroPort CardioFlow’s product offers superior biocompatibility and anti-calcification performance. These features facilitate preoperative preparation and storage transportation, significantly reducing the complexity of surgical procedures and the risk of left ventricular outflow tract obstruction.-Fineline Info & Tech
